Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure

作     者：Yi-Fei Zhang Yu-Xiang Liu Wu-Xiao Yang 

作者机构：Department of CardiologyShanxi Provincial People's HospitalShanxi Medical UniversityTaiyuan 030012Shanxi ProvinceChina Department of NephrologyShanxi Provincial People's HospitalShanxi Medical UniversityTaiyuan 030012Shanxi ProvinceChina 

出 版 物：《World Journal of Cardiology》 (世界心脏病学杂志(英文))

年 卷 期：2025年第17卷第1期

页      面：110-117页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Sodium-glucose cotransporter 2 inhibitors Type 2 diabetes mellitus Heart failure Diabetic cardiomyopathy Cardiovascular disease 

摘      要：This article discusses the study by GrubićRotkvićet al on the mechanisms of action of sodium-glucose cotransporter 2 inhibitors(SGLT2i)in patients with type 2 diabetes mellitus(T2DM)and heart failure(HF).T2DM and HF are highly comorbid,with a significantly increased prevalence of HF in patients with ***2i exhibit potential in reducing hospitalization rates for HF and cardiovascular mortality through multiple mechanisms,including improving blood glucose control,promoting urinary sodium excretion,reducing sympathetic nervous system activity,lowering both preload and afterload on the heart,alleviating inflammation and oxidative stress,enhancing endothelial function,improving myocardial energy metabolism,and stabilizing cardiac ion *** research and clinical practice will help optimize the use of SGLT2i in HF patients.